Charles River Laboratories Intl. Inc (N:CRL)

Business Focus: Biotechnology & Medical Research

Sector:  Healthcare Industry:  Biotechnology & Medical Research
 
See Regulatory Filings on SEC
Company Contact
Address: 251 Ballardvale St
WILMINGTON MA 01887-1096
Tel: N/A
Website: www.criver.com
IR: See website
<
Key People
James C. Foster
Chairman of the Board, President, Chief Executive Officer
David Ross Smith
Chief Financial Officer, Corporate Executive Vice President
David P. Johst
Corporate Executive Vice President - Human Resources, Chief Administrative Officer, General Counsel
William D. Barbo
Corporate Executive Vice President and Chief Commercial Officer
Birgit Girshick
Corporate Executive Vice President, Global Discovery and Safety Assessment, Biologics and Avian
Joseph W. LaPlume
Corporate Executive Vice President, Corporate Development and Strategy
Business Overview
Charles River Laboratories International, Inc. is an early-stage contract research company. The Company is engaged in laboratory animal medicine and science (research model technologies) and develop a portfolio of discovery and safety assessment services, both good laboratory practice (GLP) and non-GLP, which supports its clients from target identification through non-clinical development. The Company operates in three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing). The RMS segment includes Research Models and Research Model Services. The DSA segment includes Discovery Services and Safety Assessment. The Manufacturing segment includes Microbial Solutions, Avian, Biologics and Contract Manufacturing. The Company also provides a suite of products and services to support the Company's clients' manufacturing activities.
Financial Overview
For the fiscal year ended 28 December 2019, Charles River Laboratories Intl. Inc revenues increased 16% to $2.62B. Net income before extraordinary items increased 15% to $252M. Revenues reflect Discovery And Safety Assessment segment increase of 23% to $1.62B, Manufacturing Support segment increase of 8% to $465.1M, Research Models segment increase of 3% to $537.1M, United States segment increase of 16% to $1.47B.
Employees: 17,100 as of Dec 28, 2019
Reporting Currency: U.S. Dollars
Enterprise value: $7,530M as of Dec 28, 2019
Annual revenue (TTM): $2,621M as of Dec 28, 2019
EBITDA (TTM): $587.49M as of Dec 28, 2019
Net annual income (TTM): $252.02M as of Dec 28, 2019
Free cash flow (TTM): $340.42M as of Dec 28, 2019
Net Debt Last Fiscal Year: $1,649M as of Dec 28, 2019
Shares outstanding: 49,484,761 as of Mar 16, 2020
Index Membership: S&P 400 Mid Cap
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization